ACE Inhibitors versus Angiotensin Receptor Blockers in Diabetic Nephropathy: Is There a Winner?

Journal of the American Society of Nephrology

Volumn 15, Issue 5, 2004, Pages 1358-1360

  Lewis, Edmund J ^a   Lewis, Julia Breyer ^b  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; CANDESARTAN; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FOSINOPRIL; IRBESARTAN; LOSARTAN; PLACEBO; VALSARTAN;

BLOOD PRESSURE REGULATION; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DIABETIC NEPHROPATHY; DISEASE CONTROL; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; HEART FAILURE; HEART INFARCTION; HEART PROTECTION; HUMAN; HYPERTENSION; INSULIN DEPENDENT DIABETES MELLITUS; META ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT CARE; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; TREATMENT OUTCOME;

EID: 1942538297     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (19)

1. Wilmer WA, Rovin BH, Hebert CJ, Rao SV, Kumor K, Hebert LA: Management of glomerular proteinuria: A commentary. J Am Soc Nephrol 14: 3217-3232, 2003
2. Brenner BM. Regarding "Management of Glomemlar Proteinuria: A Commentary". J Am Soc Nephrol 15: 1354-1355, 2004
3. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD, for the Collaborative Study Group: The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 329: 1456-1462, 1993
4. Rodby RA, Rohde RD, Clarke WR, Hunsicker LG, Anzalone DA, Atkins RC, for the Collaborative Study Group: The irbesartan type 2 diabetic nephropathy trial: study design and baseline patient characteristics. Nephrol Dial Transplant 15: 487-497, 2000
5. Hollenberg NK, Fisher NDL, Price DA: Pathways for angiotensin II generation in intact human tissue: Evidence from comparative pharmacologic interruption of the renin system. Hypertension 32: 387-392, 1998
6. Lewis EJ, Hunsicker, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I, for the Collaborative Study Group: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 344: 851-860, 2001
7. Heart Outcomes Prevention Evaluation Study Investigators: The effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: result of the HOPE Study and the MICRO-HOPE Substudy. Lancet 355: 253-259, 2000
8. Estacio RO, Jeffers BW, Hiatt WR, Biggerstaff SL, Gifford N, Schrier RW: The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin dependent diabetes and hypertension. N Engl J Med 338: 645-652, 1998
9. Lindholm LH, Hansson L, Ekbom T, Dahlof B, Lanke J, Linjer E, et al: Comparison of antihypertensive treatments in preventing cardiovascular events in elderly diabetic patients: results from the Swedish Trial in Old Patients with Hypertension-2. STOP Hypertension-2 Study Group. J Hypertens 18: 161-165, 2000
10. Tatti P, Pahor M, Byington RP, Dimauro P, Guarisco R, Strollo G: Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM. Diabetes Care 21: 597-603, 1998
11. Lindholm LH, Ibsen H, Dahlof B, Devereux B, Beevers G, de Faire U, Fyhrquist F, Julis S, Kjeldsen SE, Kristiansson K, Lederballe-Pedersen O, Nieminen MS, Omvik T, Oparil S, Wedel H, Aurup T, Edelman J, Snapinn S, for the LIFE Study Group: Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomized trial against atenolol. Lancet 359: 1004-1010, 2002
12. Pfeffer MA, McMurray JJV, Velazquez EJ, Rouleau J-L, Kober L, Maggioni AP, Solomon SD, Swedberg K, Van de Werf F, White H, Leimberger JD, Henis M, Edwards S, Zelenkofske S, Sellers MA, Califf RM, for the Valsartan in Acute Myocardial Infarction Trial Investigators: Valsartan, captopril or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 349: 1893-1906, 2003
13. McMurrary JJV, Ostergren J, Swedberg K, Granger CB, Held P, Mychelson EL, Olofsson B, Yusuf S, Pfeffer MA for the CHARM Investigators and Committees: Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: The CHARM-Added Trial. Lancet 362: 767-771, 2003
14. Blood Pressure Lowering Treatment Trialists' Collaboration: effects of different blood-pressuring-lowering regimens on major cardiovascular events: Results of prospectively designed overviews of randomized trials. Lancet 362: 1527-1535, 2003
15. Berl T, Hunsicker LG, Lewis JB, Pfeffer MA, Porush JG, Rouleau J-L, Drury PL, Esmatjes E, Hricik D, Parika CR, Raz I, Vanhille P, Weigmann TB, Wolfe BM, Locatelli F, Goldhaber VZ, Lewis EJ, for the Collaborative Study Group: Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy. Ann Intern Med 138: 542-549, 2003
16. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving H-H, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar F for the RENAAL Study Investigators: Effects of Losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345: 861-869, 2001
17. Kaplan NM: Management of hypertension in patients with type 2 diabetes mellitus: Guidelines based on current evidence. Ann Int Med 135: 1079-1083, 2001
18. Strippoli GFM, Craig M, Schena P, Craig JC: Improved survival with ACE inhibitors compared with angiotensin II receptor antagonists in patients with diabetic nephropathy [Abstract]. J Am Soc Nephrol 14: 6A, 2003
19. Nakao N, Yoshimura A, Morita H, Takada M, Kayano T, Ideura T: Combination treatment of angiotensin-II receptor blocker and angiotensin converting enzyme inhibitor in nondiabetic renal disease (COOPERATE): A randomized controlled trial. Lancet 361: 117-124, 2003